The phase 3 NIAGARA trial randomised more than 1,000 MIBC patients to receive Imfinzi plus chemotherapy or chemotherapy alone prior to bladder removal surgery, followed by Imfinzi or no further treatment.
The Imfinzi/chemotherapy combination demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key secondary endpoint of overall survival versus neoadjuvant chemotherapy, AZ said.
It added that Imfinzi was generally well-tolerated and that no new safety concerns were observed in the neoadjuvant or adjuvant setting.
More than 614,000 patients globally are diagnosed with bladder cancer every year and MIBC, named for its growth into the muscle wall of the bladder, accounts for about one in four cases.
Approximately half of patients who undergo bladder removal surgery experience disease recurrence and AZ has outlined that treatment options that prevent disease recurrence after surgery are “critically needed”.
Susan Galbraith, executive vice president, oncology research and development, AZ, said the results from NIAGARA support the company’s strategy to “move immunotherapy to the early stages of cancer treatment”.
“This perioperative regimen with Imfinzi improved survival and reduced the rate at which patients experience disease recurrence or progression,” she added. “We are eager to bring this regimen with the potential to transform the standard of care to patients as soon as possible.”
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.